Skip to main content

SB 1223 — Missouri

Requires disclosure for certain products produced, sold, or distributed in Missouri

Introduced 2026 session Senate

This page lists STATE bills only. Open States, our source for this data, tracks state legislatures -- it has no visibility into city councils, county commissions or school boards. We don't yet have a free, storable source for local measures; see the About page for why.

Summary

SB 1223 - This act requires any product to be conspicuously labeled "Potential Gene Therapy Product" if the product has been created to act as, or otherwise exposed to processes resulting in the product acting as, a gene therapy or that could impact, alter, or introduce genetic material or a genetic change into the user or individuals exposed to the product, unless the product is reasonably known to be a gene therapy product, in which case the product shall be labeled "Gene Therapy Product".

Upon the written request of a Missouri resident, any entity producing, selling, or distributing a product in this state with the capacity to infect an individual with a disease or expose an individual to genetically modified material shall provide information to the resident on the ways in which individuals who did not directly obtain or use the product may be exposed to the product or a component of the product. These provisions apply as well to any governmental agency, product manufacturer, or organization with an interest in the production, sale, or distribution of such product, as described in the act. All entities subject to disclosure requirements under this provision shall provide the requested information within at least 21 days after receipt of the request.

Finally, any entity that makes a product available in Missouri that could infect, transmit to, or otherwise be absorbed in any individual in any way that could act as a medical intervention, vaccine, drug, or genetic modification shall obtain fully informed consent from all potential exposed individuals prior to such exposure.

This act is identical to SB 252 (2025), SB 1186 (2024), and HB 1169 (2023).
SARAH HASKINS

Official abstract, as published by the legislature.

  • SB 1223 is a bill in the Missouri Senate, 2026 session, introduced December 1, 2025.
  • Sponsored by Mike Moon.
  • Current status: introduced.
  • Most recent action (January 27, 2026): Second Read and Referred S Families, Seniors and Health Committee.
  • Subjects: Drugs and Controlled Substances, Food, Health Care, Health and Senior Services, Department of, Health, Public.

Contact your legislator about this bill

Bill text & documents

Sponsors

Primary: Mike Moon

History

  1. Introduced, completed
  2. Passed Senate, in progress
  3. Passed House, not reached yet
  4. Sent to Governor, not reached yet
  5. Signed into law, not reached yet
  1. Senate Prefiled
  2. Senate S First Read
  3. Senate Second Read and Referred S Families, Seniors and Health Committee Latest

Source: Open States. Last checked November 7, 2026. How we keep this accurate ›